Kisspeptin-10 Dosage Guide: Reported Ranges, Reconstitution & Half-Life

Kisspeptin-10 at a glance

What it is

Kisspeptin-10 — the shortest bioactive fragment (10 amino acids) of the KISS1 gene product, the upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis.

Researched for

LH-pulsatility and reproductive-axis research in men, using kisspeptin-10 itself; the related, longer kisspeptin-54 has separately been studied in human IVF-trigger and hypothalamic-amenorrhoea trials — related but distinct compounds, and the distinction matters.

Commonly reported range

Published human work used intravenous infusion, e.g. 1.5 mcg/kg/h in George et al. 2011; community-reported subcutaneous figures (~50-200 mcg) are anecdotal and have no trial behind them.

Route reported

Every published human kisspeptin-10 study used the intravenous route under clinical supervision; subcutaneous injection is what research communities discuss instead.

Reported frequency

The human studies used a single timed infusion or bolus; community reports describe once or twice daily.

Mechanism

KISS1R (GPR54) agonism on GnRH neurons, driving downstream LH and FSH release.

Plasma half-life

No established human figure. In vitro the peptide decomposes with a half-life of 1.7 min at 37 C (Liu 2013); animal work puts kisspeptin-54 at ~32 min. See the half-life section for why the widely quoted '4 minutes' is not a human measurement.

Regulatory status

Not FDA-approved for any use; reviewed (not approved) by the FDA's Pharmacy Compounding Advisory Committee in October 2024. Research/educational use only.

Reported ranges from research/community — examples, not recommendations.

What it is / mechanism

Kisspeptin-10 binds KISS1R, a G-protein-coupled receptor that spent years in the literature as the orphan receptor GPR54. Binding activates Gq/11 signalling through phospholipase C, which drives inositol trisphosphate production, intracellular calcium release and depolarisation of the GnRH neuron. GnRH released into the hypophyseal portal circulation then drives pituitary LH and FSH secretion. That places kisspeptin signalling upstream of the entire reproductive axis rather than inside it, which is the reason the compound attracted attention in the first place. The upstream position was not inferred from pharmacology; it was established by human genetics, and that is what makes it unusually solid ground. In 2003 two groups independently reported that loss-of-function mutations in GPR54 cause idiopathic hypogonadotropic hypogonadism — patients who fail to enter puberty, with intact GnRH neurons and a pituitary that responds normally to exogenous GnRH. The defect is in the signal that switches the axis on, not in the axis itself. A receptor whose absence prevents puberty in humans is, by definition, necessary for the pathway, and no animal model was required to establish it. The kisspeptin neurons themselves sit in two hypothalamic populations that do different jobs. The arcuate nucleus population co-expresses neurokinin B and dynorphin — the so-called KNDy neurons — and is generally described as the pulse generator, producing the rhythmic GnRH output that the axis depends on. A second population in the anteroventral periventricular area is associated with the pre-ovulatory LH surge in females. Kisspeptin-10 is a synthetic fragment that engages the same receptor as the endogenous peptides, which is why an exogenous dose produces LH release, and also why the timing pattern of administration matters more here than the total amount. That timing sensitivity is the practical consequence of the mechanism. Continuous exposure at a GPCR of this kind is described in the literature as producing desensitisation rather than sustained stimulation, which is why the human studies used timed infusions and boluses rather than steady exposure, and why the endogenous system is pulsatile in the first place. A mechanism that depends on a rhythm is not one where more, or more constant, administration straightforwardly means more effect.

Researched effects

The direct human evidence for kisspeptin-10 itself is small, consistent and narrow. George et al. (Journal of Clinical Endocrinology & Metabolism, 2011; PMID 21632807) infused kisspeptin-10 intravenously in healthy men and reported increased LH pulse frequency, with the lower-dose arm running at 1.5 mcg/kg/h. The same group followed it with a study in men with type 2 diabetes and hypogonadism (Clinical Endocrinology, 2013; PMID 23153270), reporting that intravenous kisspeptin-10 stimulated LH and serum testosterone. Both are proof that the receptor can be engaged pharmacologically in humans and that the downstream hormonal response follows. Neither is a trial of a self-administered product, and neither used the subcutaneous route. Separately — and this is the distinction that most vendor and community material collapses — a body of clinical work exists on kisspeptin-54, a longer peptide processed from the same KISS1 precursor. Jayasena et al. (JCEM, 2014; PMID 24517142) used intravenous kisspeptin-54 infusion to increase LH pulsatility in women with hypothalamic amenorrhoea, and the Imperial College group separately developed kisspeptin-54 as an oocyte-maturation trigger in IVF for women at risk of ovarian hyperstimulation syndrome. That research is real, peer-reviewed and clinically motivated. It is also not evidence about kisspeptin-10. The two peptides share a receptor and a C-terminal motif but differ in length, clearance and, on the available evidence, in how long a single administration keeps the receptor engaged. What the combined literature supports, stated plainly, is that kisspeptin agonism raises LH and downstream sex steroids in humans, acutely, under controlled intravenous administration. What it does not establish is any effect from repeated subcutaneous dosing of the 10-amino-acid fragment, any durable change in baseline hormone levels, or any of the body-composition and libido outcomes the compound is discussed for. The gap between the two statements is where nearly all of the marketing sits.

Dosage — reported ranges (overview)

The honest summary is that there is no established kisspeptin-10 dose, and the figures in circulation come from two incompatible sources. The published human studies used intravenous administration by body weight. George et al. 2011 ran a lower-dose infusion arm at 1.5 mcg/kg/h, with bolus and infusion protocols across the reported range delivered under clinical supervision with serial blood sampling. A weight-based intravenous infusion rate does not convert into a subcutaneous milligram figure — different route, different absorption profile, different duration of receptor exposure — so these numbers cannot be carried across to a vial and a syringe, however precise they look. Community sources separately describe subcutaneous amounts in the region of 50-200 mcg, once or twice daily. Those figures have no trial behind them. They are not scaled from the intravenous work, they are not supported by pharmacokinetic modelling, and their provenance, where it can be traced at all, is other community sources. They are recorded on this page because people will encounter them, not because they carry weight. The reconstitution table below uses 50 mcg and 150 mcg as arithmetic reference points inside that community-reported range. They are there to make the concentration math legible for someone reading a vial label. They are not a recommendation, and no dose, route or frequency is being suggested for anyone.

A printable protocol sheet with a reconstitution reference and an injection log comes with All-Access Lifetime.

Reconstitution — bac-water math

Kisspeptin-10 ships lyophilized and is reconstituted with bacteriostatic water. Concentration in mcg per unit = total mcg in the vial / (mL of bacteriostatic water x 100), because a U-100 insulin syringe holds 1 mL across 100 units. Worked example for a 5 mg (5,000 mcg) vial, using the community-reported reference amounts:

This is concentration math, not a dose recommendation.

Injection / administration basics

There is a route mismatch here that is worth stating before any handling detail. Every published human kisspeptin-10 study used intravenous administration in a clinical research setting with monitoring; the subcutaneous injection that community sources describe is a different route with a different absorption profile, and no trial has characterised it for this peptide. That is not a safety verdict, it is a statement about what is and is not known. General handling concepts — sterile technique, site rotation, working from your own vial label rather than someone else's figures, and recomputing the concentration whenever the vial size changes — are covered here as general information. The detailed workflow comes with All-Access Lifetime, which includes the printable protocol sheet and injection log for every compound. This is general educational information, not a personal administration protocol; a qualified professional should guide any actual use.

Half-life & frequency rationale

The figure of roughly 4 minutes is quoted almost everywhere kisspeptin-10 is discussed, and it is worth being precise about where it does and does not come from, because this page previously carried it as a human measurement and that overstated the evidence. What is documented is chemical stability. Liu et al. (2013; PMID 23524040) measured decomposition half-lives for kisspeptin-10 in vitro of 6.8 minutes at 4 C, 2.9 minutes at 25 C and 1.7 minutes at 37 C. That is a statement about how quickly the molecule falls apart at body temperature in a controlled preparation, which is a real and relevant property, but it is not a plasma pharmacokinetic half-life measured in people. Comparative animal work (d'Anglemont de Tassigny et al., 2017; PMID 28464043) puts kisspeptin-54 at approximately 32 minutes in the bloodstream, with kisspeptin-10 substantially shorter. So the defensible statement is: kisspeptin-10 is cleared or degraded very rapidly, on a scale of a few minutes rather than hours, and markedly faster than kisspeptin-54 — and no well-established human plasma half-life for the 10-amino-acid fragment appears in the indexed literature. Publishing the absence is more useful than repeating a number whose source turns out to be an in vitro degradation assay. The practical implication is the same either way, and it is significant. A compound that disappears within minutes does not maintain a steady blood level between administrations. Whatever effect a single administration produces is acute and over quickly, which is also why the clinical studies measured LH pulses during an infusion rather than hormone levels the following day. It is likewise part of why kisspeptin-54, with its longer duration, was the compound taken into the extended IVF-trigger work.

Stacking — overview

Community discussion sometimes pairs kisspeptin-10 with growth-hormone-axis peptides such as sermorelin, on the reasoning that the two act on separate hormonal systems and should therefore not interfere. The reasoning is coherent as far as it goes, and it is worth being clear that it is reasoning rather than evidence: no clinical trial has studied kisspeptin-10 in combination with anything. Each combination is covered in depth — the mechanism-level rationale, what is reported in practice, and combination-specific cautions — in the paid Kisspeptin-10 Stacking Module included with this guide.

For how combinations are grouped by research context, the named blends, and why a pre-mixed blend vial cannot be calculated from its total milligrams, see the peptide stacks guide.

Storage & handling

• Lyophilized (unmixed): store cold; long-term typically -20 C / freezer; stable refrigerated short-term.
• Reconstituted: refrigerate (~2-8 C); commonly reported usable window ~2-4 weeks; keep away from light; do not freeze once mixed.
• Worth noting for this peptide specifically: the in vitro decomposition data show it degrading appreciably faster at 25 C than at 4 C, so time spent at room temperature costs more here than it does for more stable compounds.

Evidence File

The Kisspeptin-10 Evidence File: The Trials Filed Under a Different Name

Nearly every published summary of kisspeptin-10 rests on two papers, and both are real. The problem is what they leave out. The largest body of human work on this peptide is registered under two other names, and a search for the name printed on the vial does not return it. This file rebuilds the record from the registry outward: every trial that administered the compound under any of its three designations, what each one gave and by which route, which have posted results and which have not, where the chronic-dosing question was tested under placebo control, and what the answer was.

• 12 completed registered trials, filed under three names
• 3 of those 12 have posted results; the rest have none
• 2 chronic-dosing Phase 2a trials terminated for missing their testosterone endpoint
• 8-fold to 31-fold gap between community and trial daily amounts

Sourcing File

The Kisspeptin-10 Sourcing File: Four Failure Modes and the Arithmetic That Catches Them

A certificate for this peptide can be entirely accurate and still leave the two most important questions open. Kisspeptin-10 has a specific chemistry that produces specific ways of going wrong, and each of them has a number attached that a reader can check against the printed page without any equipment. This file supplies those numbers: the verified identity block and the mass forms a report might legitimately quote, the two near-mass substitutions that survive a rounded molecular weight, what a federal review could and could not find when it went looking for a specification, and the salt arithmetic that decides how much compound a vial actually holds.

• 1301.6305 Da neutral monoisotopic, reproduced independently
• 0.984 Da separates the intended amide from the free-acid failure
• 820 mcg spread in a nominal 5 mg vial across plausible salt forms
• No published impurity profile, by the regulator's own named searches

Benefit & Outcome Review

The Kisspeptin-10 Benefit Review: Nine Claims and One Inflection Point

Grading kisspeptin-10 claims as strong, moderate or weak produces the wrong answer, because for this compound the decisive variable is not how good the study was but when the measurement was taken. One published human protocol in this molecular class ran long enough for that to matter, and what it recorded reorganises every claim below it. This review sets that time course out first, then grades nine marketed claims against it, separating what was measured in people from what was measured in rodents and cells, naming the exact searches behind every absence, and tracing the two most-quoted numbers back to the molecule they actually came from.

• 9 marketed claims graded, 1 supported outright
• 3 preclinical datasets absent: genotoxicity, reproductive toxicity, cancer
• 1 real-world report of the community protocol, describing unwanted effects
• roughly 32 percent fall in the LH response between day 1 and day 12

Guide FAQ

Quick answers about guide scope, access, and educational use context.